Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.90 | N/A | -1.35% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.90 | N/A | -1.35% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism about the company's future. They emphasized their commitment to innovation despite the EPS miss.
Management highlighted ongoing efforts in drug development.
They expressed confidence in future pipeline advancements.
Despite missing on EPS, Crinetics Pharmaceuticals saw a positive stock reaction, rising 5.66%. This increase may reflect investor confidence in the company's future drug development efforts. The lack of revenue data and guidance leaves some uncertainty, but management's optimistic tone suggests potential for growth ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WORKDAY INC A
Feb 26, 2024